使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Hello, and welcome to the Phathom Pharmaceuticals Third Quarter 2026 Earnings Results Call. (Operator Instructions) With that, I would like to turn the call over to Eric Shirelli, Phathom's Head of Investor Relations. Please go ahead.
大家好,歡迎參加 Phathom Pharmaceuticals 2026 年第三季財報電話會議。(接線員指示)接下來,我想把電話交給 Phathom 投資人關係主管 Eric Shirelli。請開始。
Eric Sciorilli - Head of Investor Relations
Eric Sciorilli - Head of Investor Relations
Thank you, operator. Hello, everyone, and thank you for joining us this morning to discuss Phathom's third quarter 2026 results. This morning's presentation will include remarks from Steve Basta, our President and CEO, and Sanjeev Narula, our Chief Financial and Business Officer. Before we begin, let me remind you that we'll be making a number of forward-looking statements throughout today's presentation. These forward-looking statements involve risks and uncertainties, many of which are beyondPhathom's control. Actual results may materially differ from the forward-looking statements, and any such risks may materially adversely affect our business and results of operations and the trading. For Phathom's common stock. Discussion of these statements and risk factors is available on the current Safe Harbor slide as well as in the Risk Factors section of our most recent Form 10-K, today's 10-Q and subsequent SEC filings. All forward-looking statements made on this call are based on the beliefs ofPhathom as of this date and Phathom disclaims any obligations to update these statements.
謝謝,接線員。各位早安,感謝各位今天早上加入我們,一同討論 Phathom 2026 年第三季的業績。今天早上的簡報將包含我們總裁暨執行長 Steve Basta,以及我們財務與商務長 Sanjeev Narula 的發言。在開始之前,提醒各位,我們在今天的簡報中將會提出多項前瞻性陳述。這些前瞻性陳述涉及風險與不確定性,其中許多超出 Phathom 的控制範圍。實際結果可能與前瞻性陳述有重大差異,且任何此類風險都可能對我們的業務、營運結果以及 Phathom 普通股的交易造成重大不利影響。Phathom 普通股。關於這些陳述與風險因素的討論,可參閱目前的「安全港」投影片,以及我們最近一期 Form 10-K、今日的 10-Q 與後續向 SEC 提交文件中的「風險因素」章節。本次電話會議中所作的所有前瞻性陳述,均以截至本日 Phathom 的信念為基礎,Phathom 不承擔更新這些陳述的任何義務。
Later in the call, we will be commenting on both GAAP and non-GAAP financial measures. Specifically, in the scope of this discussion, when we refer to cash operating expenses, please note we are referring to the non-GAAP form of this measure, which excludes non-cash stock-based compensation. As always, detailed reconciliations between our non-GAAP results and the most directly comparable GAAP measures are included in this morning's press release. With that, I will now turn the call over to Steve Basta, BAVM's President and CEO, to kick us off. Steve.
稍後在電話會議中,我們將同時評論 GAAP 與非 GAAP 財務衡量指標。具體而言,在本次討論範圍內,當我們提到現金營運費用時,請注意我們指的是該指標的非 GAAP 形式,其中排除了非現金的股票基礎薪酬。一如既往,我們的非 GAAP 結果與最直接可比的 GAAP 指標之間的詳細調節表,已包含在今天早上的新聞稿中。接下來,我將把電話交給 BAVM 總裁暨執行長 Steve Basta,為我們揭開序幕。Steve。
Steven Basta - President, Chief Executive Officer, Director
Steven Basta - President, Chief Executive Officer, Director
Thank you, Eric, and thank you, everyone, for joining our call this morning. I'm pleased to share with you this morning the solid executionPhathom posted in the third quarter.
謝謝你,Eric,也謝謝各位今天早上參加我們的電話會議。我很高興在今天早上與各位分享 Phathom 在第三季所展現的穩健執行成果。
Over the past year and a half,Phathom has significantly strengthened our financial position. In Q3, we delivered our second consecutive quarter of positive operating profit, excluding stock-based compensation, and once again generated positive cash flow.
在過去一年半中,Phathom 已大幅強化我們的財務狀況。在第三季,我們連續第二季達成正向營業利益(不含股票基礎薪酬),並再次產生正向現金流。
This quarter's net revenues grew by about 71% compared to Q3 last year and about 14% compared to last quarter.
本季淨營收較去年第三季成長約 71%,較上一季成長約 14%。
We are focused on making it easier for physicians to prescribe Broquezna and for patients with GERD to get it.
我們專注於讓醫師更容易開立 Broquezna,並讓 GERD 患者更容易取得該藥。
The physicians we talked to are already convinced of the clinical value of Broquezna.
我們訪談的醫師已經相信 Broquezna 的臨床價值。
In recent market research, 97% of HCPs we surveyed rated Broquezna's efficacy is favorable compared to other GERD treatment options.
在近期的市場研究中,我們調查的醫療照護專業人員(HCP)中有 97% 認為 Broquezna 的療效相較其他 GERD 治療選項更具優勢。
Our job now is to make it as easy as possible for providers to prescribe Voquezna for GERD and for their patients to be able to access it affordably.
我們現在的工作,是讓醫療提供者能盡可能容易地為 GERD 開立 Voquezna,並讓其病患能以可負擔的方式取得藥物。
Over the last few months, we've implemented our Access First initiative, including multiple levers to help improve Vaquezna's access experience for physicians and patients.
在過去幾個月,我們推動了「Access First」倡議,透過多項槓桿來協助改善醫師與病患對 Vaquezna 的可近性體驗。
Our reps are making meaningful headway in GI offices every day, and we believe we are well positioned to close out the year with a strong fourth quarter.
我們的業務代表每天在腸胃科(GI)診所都取得實質進展,我們相信我們已做好準備,以強勁的第四季為今年畫下句點。
I'd like to turn briefly to a few key financial highlights for the quarter, and then Sanjeev will provide further commentary during his portion of the call.
我想先簡要說明本季幾項關鍵財務亮點,接著 Sanjeev 將在他發言的部分提供進一步評論。
For Q3, we reported net revenues of $84.7 million, cash operating expenses of $60.5 million, positive operating profit of $5.8 million, both of those operating metrics excluding stock-based compensation, and cash generated from operations of about $2.1 million. We are proud of our results this quarter and reiterate our full-year revenue guidance of. $310 million to $325 million heading into Q4.
第三季我們公布淨營收 8,470 萬美元,現金營運費用 6,050 萬美元,正向營業利益 580 萬美元(上述兩項營運指標均不含股票基礎薪酬),以及營運活動產生的現金約 210 萬美元。我們為本季成果感到自豪,並重申全年營收指引為3.10 億至 3.25 億美元,並以此展望進入第四季。
A few quick notes on our commercial metrics for Q3. Since launch through October 16, over 2 million Voquezna prescriptions have been filled. After achieving our first million prescriptions just over two years into our launch, we're thrilled to have reached our second million milestone less than a year later.
關於第三季的商業化指標,簡要補充幾點。自上市至 10 月 16 日,Voquezna 已累計配發超過 200 萬張處方。在上市後略超過兩年達成第一個 100 萬張處方後,我們很高興在不到一年內就達成第二個 100 萬張里程碑。
Of the approximately 380,000 prescriptions that were filled in Q3, about 248,000 were covered prescriptions, representing approximately 65% of the total, while about 132,000 were filled with cash pay. Compared to last quarter, this represents 19% growth in covered volume and 6% growth in cash volume.
在第三季約 38 萬張已配發的處方中,約 24.8 萬張為有保險給付的處方,約占總量的 65%;另約 13.2 萬張為自費配藥。相較上一季,這分別代表給付量成長 19%,自費量成長 6%。
One note on data reporting, IQVIA recently adjusted their projection methodology for Voquezna , which took effect for the data week ending October 9th. These types of updates are commonplace by IQVIA as brands mature.
關於數據回報的一點說明:IQVIA 近期調整了 Voquezna 的推估方法,並自截至 10 月 9 日的資料週起生效。隨著品牌成熟,IQVIA 進行此類更新相當常見。
As we discussed on our last call, we believe the key hurdle to broader use of Voquezna in the treatment of GERD is making it easier for physicians to prescribe it and for patients to obtain it. When physicians consider whether to prescribe Voquezna for GERD, they consider patient need, the amount of effort required of their staff, and their confidence level that the patient will actually receive the drug at an affordable cost.
如同我們在上次電話會議中所討論的,我們認為 Voquezna 在 GERD 治療上更廣泛使用的關鍵門檻,在於讓醫師更容易開立、讓病患更容易取得。當醫師考慮是否為 GERD 開立 Voquezna 時,他們會考量病患需求、其診所人員需要投入的作業量,以及他們對病患是否能以可負擔成本實際拿到藥物的信心程度。
To address this, we've shifted our sales force to focus on access first. Our reps are educating physicians and their office staff on PA requirements, the support available through our pharmacy partner Blink, and multiple patient support programs.
為了因應這點,我們已將銷售團隊的重點轉向「access first」。我們的業務代表正在教育醫師及其診所人員了解事前授權(PA)要求、透過我們藥局合作夥伴 Blink 可獲得的支援,以及多項病患支持方案。
This is not a complex strategy, but it requires steady blocking and tapping, office by office and physician by physician, which we acknowledge takes time.
這不是一個複雜的策略,但需要穩健、持續地逐一診所、逐一醫師推進;我們也理解這需要時間。
Increasing physician utilization of Blink is a key part of our Access First strategy. When prescriptions are sent to BlinkRx. We observe higher PA submission and approval rates, and ultimately overall TRx fill rates are significantly higher compared to retail pharmacies.
提高醫師對 Blink 的使用率,是我們 Access First 策略的關鍵部分。當處方送至 BlinkRx 時,我們觀察到更高的 PA 送件與核准率,最終整體 TRx 配藥率也顯著高於零售藥局。
We continue to educate HCPs that BlinkRx assists with navigating the prior authorization process with HCPs and patients, keeping patients informed throughout the prescription fulfillment process, automatically applying our patient support programs when available to the patient, and helping patients access the lowest out-of-pocket cost available to them.
我們持續向醫療照護專業人員(HCP)說明:BlinkRx 可協助 HCP 與病患處理事前授權流程、在處方配藥流程中持續向病患提供資訊、在病患符合資格時自動套用我們的病患支持方案,並協助病患取得其可用的最低自付額。
At the end of Q3, we rolled out a $0 copay offering as part of our Access First strategy available only through BlinkRx.
在第三季末,我們推出了 $0 自付額(copay)方案,作為 Access First 策略的一部分,且僅透過 BlinkRx 提供。
We believe this new offering will encourage prescribers to use BlinkRx.
我們相信這項新方案將鼓勵開立處方者使用 BlinkRx。
Rather than focusing on the potential difference in out-of-pocket costs between Voquezna and a generic BPI, physicians can now consider whether Voquezna is an appropriate treatment option for their patients with GERD, knowing that eligible commercially insured patients may pay as little as $0 out of pocket.
醫師不再需要把重點放在 Voquezna 與學名 BPI 之間可能存在的自付額差異;現在,醫師可以在了解符合資格的商業保險病患自付額最低可至 $0 的前提下,評估 Voquezna 是否為其 GERD 病患的合適治療選項。
We are seeing positive early signals of the impact of these programs, and we will continue to work to improve perceptions of access and affordability for Voquezna .
我們已看到這些方案帶來的正向早期訊號,並將持續努力改善市場對 Voquezna 可近性與可負擔性的認知。
Turning briefly to our development programs. In EOE, we anticipate reporting top-line data from our Phase II FALCON EOE trial in Q4. The primary endpoint in this trial focuses on histologic improvement, a reduction of eosinophil counts after 12 weeks of treatment. Symptom improvements will also be evaluated as secondary endpoints. The additional 12-week open-label safety extension portion of this trial is ongoing.
接著簡要談談我們的研發計畫。在 EOE 方面,我們預期將於第四季公布第二期 FALCON EOE 試驗的主要(top-line)數據。此試驗的主要終點著重於組織學改善,也就是治療 12 週後嗜酸性球計數的下降。症狀改善也將作為次要終點進行評估。本試驗額外的 12 週開放標籤安全性延伸期仍在進行中。
Our Phase 3 Falcon-NERD 302 study of Voquezna for as-needed treatment of non-erosive GERD is currently enrolling patients. In this trial, patients are treated daily for four weeks with Vaquezna, then are randomized to as-needed treatment with Voquezna or with placebo for six months.
我們針對 Voquezna 用於按需治療非糜爛性 GERD 的第三期 Falcon-NERD 302 研究目前正在招募受試者。在此試驗中,患者先以 Vaquezna 每日治療四週,之後隨機分派為期六個月的按需治療,使用 Voquezna 或安慰劑。
The primary endpoint will evaluate for Quesna's ability to provide complete release by two hours that is sustained for 24 hours. We expect top-line data in Q1 2028 and believe that if the trial is successful and we gain approval, we would unlock an incremental market opportunity for the many patients with GERD who don't want to continue taking BPIs on a daily basis.
主要終點將評估 Quesna 在兩小時內達到完全緩解並可維持 24 小時的能力。我們預期於 2028 年第一季取得主要數據,並相信若試驗成功且獲得核准,將可為許多不希望每日持續服用 BPI 的 GERD 患者開啟額外的市場機會。
Lastly, I'd like to briefly touch on recent developments related to Voquezna 's exclusivity period.
最後,我想簡要談談近期與 Voquezna 專屬期相關的進展。
On October 21, 2026, BDR Pharmaceuticals filed suit against the FDA, principally challenging the FDA's alleged refusal to receive their ANDA referencingPhathom's NDA for Voquezna .
2026 年 10 月 21 日,BDR Pharmaceuticals 對 FDA 提起訴訟,主要挑戰 FDA 被指稱拒絕受理其引用 Phathom 之 Voquezna NDA 的 ANDA。
Their suit alleges that the FDA improperly applied the GAIN Act to extend the NCE exclusivity for Voquezna tablets.
其訴狀主張 FDA 不當適用 GAIN Act,以延長 Voquezna 錠劑的 NCE 專屬期。
A second purported ANDA filer has subsequently filed a notice that it intends to move to consolidate its case with BDRs.
隨後,第二家自稱的 ANDA 申請者也提交通知,表示擬申請將其案件與 BDR 的案件合併審理。
Recall, the FDA conducted a thorough review of this matter via Phathom's citizens petition and came to a decision in June of 2025. Their decision was that 10 years of NCE exclusivity as extended by the GAIN Act would apply to all products containing Voquezna .
回顧一下,FDA 已透過 Phathom 的公民請願對此事進行全面審查,並於 2025 年 6 月作出決定。其決定為:由 GAIN Act 延長之 10 年 NCE 專屬期將適用於所有含有 Voquezna 的產品。
The FDA thereby recognized NCE exclusivity for Voquezna tablets through May 3, 2032 and updated the Orange Book accordingly.
因此,FDA 認定 Voquezna 錠劑的 NCE 專屬期將持續至 2032 年 5 月 3 日,並相應更新《橘皮書》。
On October 23, 2026, the FDA opened a public docket for 30 days to solicit comment on legal and regulatory questions raised by BDR suit, which they felt were new compared to our citizen petition request. We believe the FDA arrived at the correct decision following our citizen petition.Phathom has intervened in the litigation filed by BDR to continue to defend our statutory exclusivity. We intend to vigorously defend our position.
2026 年 10 月 23 日,FDA 開放為期 30 天的公開意見徵詢檔案(public docket),以徵求對 BDR 訴訟所提出之法律與監管問題的意見;FDA 認為這些問題相較於我們的公民請願請求屬於新的議題。我們相信 FDA 在審理我們的公民請願後作出了正確決定。Phathom 已介入 BDR 提起的訴訟,以持續捍衛我們的法定專屬權。我們將堅決捍衛我們的立場。
I will now turn the call over to Sanjeev to take you through our financial updates. Sanjeev.
接下來我將把電話交給 Sanjeev,帶各位了解我們的財務更新。Sanjeev。
Sanjeev Narula - Chief Financial and Business Officer
Sanjeev Narula - Chief Financial and Business Officer
Thank you, Steve, and hello, everyone.
謝謝你,Steve,大家好。
We're pleased with our Q3 financial results, and I believe we have a strong momentum heading into the end of 2026.
我們對第三季的財務結果感到滿意,我相信我們在邁向 2026 年底之際具備強勁動能。
With that, let's go into our results.
接下來我們來看業績表現。
Revenues of Q3 were $84.7 million, reflecting year-on-year growth of $35.2 million or 71%.
第三季營收為 8,470 萬美元,較去年同期增加 3,520 萬美元,年增 71%。
Sequentially, revenue grew $10.4 million or 14% over Q2 2026.
按季比較,營收較 2026 年第二季增加 1,040 萬美元,成長 14%。
Covered prescription trends were strong, growing about 19% sequentially. While we observed wholesale inventory at the end of Q3 to be slightly lower than the levels at the end of Q2, we still delivered solid revenue growth.
已覆蓋處方(covered prescription)趨勢強勁,按季成長約 19%。雖然我們觀察到第三季末的批發通路庫存略低於第二季末水準,但我們仍實現了穩健的營收成長。
Our gross-to-net discount for Q3 came in slightly below our guidance. The results were driven by the channel mix for Vaquesna prescription and by decreasing accruals in connection with lower wholesale inventory levels.
第三季的毛額到淨額折扣(gross-to-net discount)略低於我們的指引。結果主要受 Vaquesna 處方的通路組合影響,以及因批發庫存水準較低而使相關應計項目下降所致。
Both items had a marginous positive impact on our gross-to-net for this quarter.
這兩項因素在本季對我們的毛額到淨額帶來些微正面影響。
Our gross profit margin landed at approximately 78% for Q3 below our guidance.
第三季毛利率約為 78%,低於我們的指引。
The variance was due to the inclusion of certain one-time charges in our cost of revenues.
差異主要是因為我們的營收成本中包含某些一次性費用。
Third quarter cash operating expenses were about $60.5 million, an anticipated slight step up compared to last quarter, which we outlined during our previous earnings call.
第三季現金營運費用約為 6,050 萬美元,較上一季如預期小幅上升,這點我們在前次財報電話會議中已說明。
On R&D side, the increase was primarily due to incremental clinical trial cost for our EOE and as-needed studies.
在研發(R&D)方面,增加主要來自我們 EOE 與按需研究的額外臨床試驗成本。
On SG&A side, the increase was primarily tied to investments in our sales and marketing effort, including our Access First initiatives.
在銷售、一般及行政(SG&A)方面,增加主要與我們在銷售與行銷投入相關,包括我們的 Access First 計畫。
I'm proud to report that for second consecutive quarter, we have delivered operating profitability and generated cash from operations, ending the quarter with $184.6 million in cash and cash equivalent.
我很自豪地報告,我們已連續第二季實現營運獲利並產生營運現金流,季末現金及約當現金為 1.846 億美元。
This quarter's performance clearly demonstrate a pivot in the evolution of the company.
本季表現清楚展現公司發展進程中的轉折點。
Our capital structure is supported by a strong balance sheet.
我們的資本結構由強健的資產負債表所支撐。
Beginning October 1, 2026. Our cash hold requirement across our capital structure shifted to a covenant set forth by our revenue, interest, and financial investment. At that time, our cash holding requirement becomes about $119 million right in line with approximately $120 million we anticipated and communicated during our Q4 2025 call.
自 2026 年 10 月 1 日起。我們資本結構下的現金持有要求,已轉為由我們的營收、利息與金融投資所規範之契約條款(covenant)。在該時點,我們的現金持有要求約為 1.19 億美元,與我們在 2025 年第四季電話會議中預期並對外溝通的約 1.20 億美元一致。
With $184.6 million in cash and cash equivalent. On the balance sheet at the end of Q3. We have significant cash balance above this requirement, especially when considering recent positive cash generation trends.
以 1.846 億美元的現金及約當現金。在第三季末的資產負債表上,我們的現金餘額顯著高於此一要求,尤其考量近期正向的現金產生趨勢。
Going forward, we expect this requirement to step down slightly over next year as revenue increases and we make additional royalty payments.
展望未來,隨著營收增加且我們支付額外權利金,我們預期該要求在明年將略為下調。
Beginning October 1, 2027, the relative holding threshold increases, so we anticipate our current requirements will be modestly higher.
自 2027 年 10 月 1 日起,相對持有門檻將提高,因此我們預期當時的要求將較目前略高。
Thereafter. We expected to decline based on the terms of agreement, anticipated increases in revenue and future loyalty payments.
其後。我們預期將依協議條款、預期營收增加以及未來權利金支付而下降。
As we've communicated previously, we believe based on current expectations that our current cash on hand and anticipated future cash generated from operations will be sufficient to invest in our business and satisfy all covenants at all times without the need for another debt or equity raise.
如我們先前所溝通,基於目前的預期,我們相信現有手頭現金以及未來由營運所產生的預期現金,將足以支持我們投資業務並在任何時點滿足所有契約條款,而無需再進行任何債務或股權募資。
Now let me turn to our latest financial guidance to close 2026.
接下來我將說明我們最新的 2026 年全年財務指引。
We are maintaining revenue guidance of $310 million to $325 million for full-year 2026.
我們維持 2026 年全年營收指引為 3.10 億至 3.25 億美元。
Given our year-to-date Q3 results, we expect our full-year 2026 close-to-net discount will come in towards the lower part of our 55% to 59% guidance range.
基於截至第三季的年初至今(YTD)結果,我們預期 2026 年全年 close-to-net 折扣將落在我們 55% 至 59% 指引區間的較低端。
We continue to anticipate our gross margin will be approximately 80%.
我們仍預期毛利率約為 80%。
As for spend, we maintain our cash operating expense guidance, excluding stock-based compensation of $235 million to $245 million, and we believe we are tracking toward the lower part of that range.
在費用方面,我們維持現金營運費用指引(不含以股票為基礎之薪酬)為 2.35 億至 2.45 億美元,且我們認為目前進度將落在該區間的較低端。
We believe our second consecutive quarter of operating profitability represents a sustainable pattern going into Q4, including in total for full year 2026 and beyond.
我們相信連續第二季的營運獲利,代表進入第四季乃至 2026 年全年及其後期間的一種可持續模式。
As for cash flow, we maintain our guidance of reaching durable positive cash flow in 2027.
在現金流方面,我們維持於 2027 年達成可持續正向現金流的指引。
Overall, Q3 was solid quarter for Phathom, and we're proud of our results.
整體而言,第三季對 Phathom 來說是穩健的一季,我們對成果感到自豪。
I feel good about our financial strength and ability to execute going into Q4 and beyond.
我對我們的財務實力以及在第四季及其後的執行能力感到有信心。
Thank you, as always, to our employees for the dedication in bringing Voquezna to millions of good patients in need.
一如既往,感謝我們的員工致力於將 Voquezna 帶給數以百萬計有需求的患者。
With this, I'll turn it back to the operator for your questions. Operator, please open the line for Q&As.
接下來我把時間交回給接線員,進行提問。接線員,請開放問答線路。
Operator
Operator
(Event Instructions)
(活動說明)
Our first question or comment comes from the line of Kristen Kluska from Cantor Fitzgerald. Your line is open.
我們的第一個問題或意見來自 Cantor Fitzgerald 的 Kristen Kluska。您的線路已開通。
Kristen Kluska - Research Analyst
Kristen Kluska - Research Analyst
Hi, good morning, everybody, and congrats on a nice revenue quarter. Two questions for me. The first on some of the initiatives you've taken to help with access, can you walk us through specifically other than the BlinkRx updates? How this is converting to better prescriptions and access. So essentially, are you helping the providers to walk through what requirements they are going to need when they file for this, or what are the specifics there? And then my second question, I can appreciate, you probably can't comment much on some of the ongoing.
嗨,大家早安,恭喜本季營收表現不錯。我有兩個問題。第一個是關於你們為改善可近性所採取的一些措施,除了 BlinkRx 的更新之外,能否具體說明這些措施如何轉化為更好的處方與可近性?也就是說,你們是否在協助醫療提供者了解他們在申請時需要符合哪些要求,或具體作法是什麼?然後第二個問題是,我理解你們可能無法對一些仍在進行中的事項多做評論。
Lawsuits stuff related to the GAIN Act, but I was hoping you could just let us know what your expectation on next steps are.
與 GAIN 法案相關的訴訟事項,但我原本希望您能簡單跟我們說明一下,您對接下來步驟的預期是什麼。
Thank you.
謝謝。
Steven Basta - President, Chief Executive Officer, Director
Steven Basta - President, Chief Executive Officer, Director
Kristen, thanks so much for both of the questions.
Kristen,非常感謝你提出這兩個問題。
Let me just take each of them. First, the initiatives for access. So the phenomenon of access, you can think of in two different ways. One is sort of in reality, actually three different contexts. One is in reality we've got pretty good coverage from payers with north of 80% of commercial lives covered. So the actual market access coverage for the product is solid and broad-based.
我來逐一回應。首先是可近性(access)的相關措施。所謂可近性的現象,你可以用兩種不同方式來看。其中一種其實在現實中又可分成三種不同情境。第一,在現實層面,我們從付款方那邊已取得相當不錯的涵蓋率,商業保險人群中有超過 80% 的受保生命數被涵蓋。因此,產品的實際市場准入/給付涵蓋是穩健且廣泛的。
The second way of thinking about it is how much work is it for the physicians to complete the process and how accurately is the PA process completed and sort of a third part of it is affordability. So let's just sort of and perceptions around how much work it is and perceptions around affordability. So if you think about.
第二種思考方式是:醫師完成整個流程需要多少工作量、事前授權(PA)流程完成得有多精準;第三部分則是可負擔性。所以我們來談談大家對工作量的觀感,以及對可負擔性的觀感。如果你想想看。
Each of those elements. Our market access status with payers is solid. We've got really good commercial coverage. We are very pleased with where we stand in that process.
上述每一個要素。我們在付款方端的市場准入狀態很穩健。我們有非常好的商業保險涵蓋。我們對於目前在這個流程中的位置非常滿意。
Prior authorization logistics perspective. Our prior authorizations are actually really straightforward, but there is some education of physicians regarding, for example, capturing prior PPI use in the medical notes, because PPIs might have been prescribed by a primary care physician, might not be in the records for the GI physician who's prescribing the product. And so just capturing that in the medical notes makes the prior authorization simpler when the medical assistant in the office is submitting the prior authorization to get that covered. And while many plans have only one prior PPI that's required, some plans might require two prior PPIs. So part of what we're doing is just educating physicians around here's what you need to document in the medical notes when you're seeing the patient just to make sure that the PA goes through smoothly. Educating the medical staff around here are the plans in your region, who requires one prior PPI, who might require two prior PPIs. And there's a very granular conversation happening on a physician-by-physician level, on a staff-by-staff, office-by-office level to work through what's needed for this prior authorization. It's a pretty simple document. It varies a little bit by plan, what are the local dominant plans in your area, and just making sure that we are building both.
從事前授權的作業物流角度來看。我們的事前授權其實非常直接,但需要對醫師做一些教育,例如在病歷註記中記錄先前使用 PPI 的情況,因為 PPI 可能是由基層照護醫師開立,未必會出現在開立本產品的腸胃科醫師的病歷紀錄中。因此,只要把這些資訊補進病歷註記,當診所的醫療助理提交事前授權以取得給付時,流程就會更簡單。而且雖然許多保險計畫只要求先前使用過一種 PPI,但有些計畫可能要求兩種先前 PPI。 所以我們正在做的一部分工作,就是教育醫師:在看診時你需要在病歷註記中記錄哪些內容,才能確保 PA 順利通過。同時也教育醫療行政人員:你所在區域有哪些保險計畫、哪些只要求一種先前 PPI、哪些可能要求兩種先前 PPI。 目前我們正在以非常細緻的方式,在逐位醫師、逐位員工、逐家診所的層級進行溝通,釐清完成這份事前授權所需的內容。這份文件相當簡單。不同計畫之間會有些微差異,取決於你所在地區的主流保險計畫是哪些,而我們要做的就是確保我們同時在建立兩件事。
The success rate because capturing prior PPI use in your medical notes improves the success rate. Submitting the PAs with all of the prior PPIs documented increases the success rate, but also we're improving perception and the confidence level that that access is going to go through. So a lot of what we've been doing is around educating around the process and educating around confidence that your patients can in fact get it. And a key part of that also is if you send it to Blink. They're going to help your staff with this process and introducing the $0 copay improves perceptions of affordability. So there's one, improved perceptions of how the access process flows, but also improved perceptions of affordability at the same cost as a PPI. So that's -- there are a number of initiatives that work both through Blake and through traditional retail pharmacies, but it's really around streamlining that process and the knowledge base at the office level.
成功率,因為在病歷註記中記錄先前 PPI 使用情況會提高成功率。在提交 PA 時把所有先前 PPI 都記錄清楚會提高成功率;同時我們也在改善大家的觀感與信心,讓他們相信這個准入是能通過的。因此,我們做的很多工作都圍繞在流程教育,以及建立「你的病人確實能拿到藥」的信心。其中一個關鍵部分也包括:如果你把處方送到 Blink,他們會協助你的員工完成這個流程,而導入 0 美元自付額($0 copay)也能改善對可負擔性的觀感。所以,一方面是改善大家對准入流程運作方式的觀感,另一方面是在與 PPI 相同成本的前提下,改善對可負擔性的觀感。 也就是說——我們有多項措施同時透過 Blink 以及傳統零售藥局來推動,但核心重點在於簡化流程,以及提升診所端的知識與熟悉度。
And then in terms of the litigation, obviously the next step that was announced on our press release on Monday is that FDA has opened up the open docket. Litigation goes through many steps and we're going to sort of -- we're going to try to not predict exactly what happened. Happens in each step of this process because it's an inherently fluid process as you go through these kinds of litigation matters. I'm sure you've seen dozens of companies work through this process because this is commonplace in our industry. But we'll reserve trying to predict what the next steps are in this process.
至於訴訟方面,顯然下一步就是我們在週一新聞稿中宣布的:FDA 已開放公開徵詢意見的案卷(open docket)。訴訟會經歷許多步驟,而我們將——我們會盡量不去精準預測會發生什麼。在這個流程的每一步會發生什麼,因為這類訴訟案件在推進時本質上是動態且變動的。我相信你也看過數十家公司走過這個流程,因為在我們產業這是很常見的。但我們會保留,不去嘗試預測接下來在這個流程中的下一步會是什麼。
Kristen Kluska - Research Analyst
Kristen Kluska - Research Analyst
Thanks, Steve.
謝謝,Steve。
Operator
Operator
Thank you. Our next question or comment comes from the line of Martin Auster from Raymond James. Mr. Auster, your line is now open.
謝謝。我們下一個提問或意見來自 Raymond James 的 Martin Auster。Auster 先生,您的線路已開通。
Martin Auster - Equity Analyst
Martin Auster - Equity Analyst
Yeah, hey, thanks for taking my question.
是的,嗨,謝謝讓我提問。
I wanted to ask a little bit more about the Access First initiatives. I like seeing those a lot, Steve.
我想再多問一點關於 Access First 措施的內容。Steve,我很樂見你們推出這些措施。
I guess I was curious if you could talk a little bit more about sort of the eligibility criteria for folks that are being kind of referred through BlinkRx. Who would be eligible for $0 copay? What sort of proportion of scripts do you think that might sort of benefit in terms of patients out of pocket? And then do you anticipate sort of any longer-term rethinking around gross to net as a result of that benefit to patients?
我想知道你是否能再多談一些,關於透過 BlinkRx 轉介的患者,其資格條件大概是什麼。哪些人符合 0 美元自付額($0 copay)的資格?你認為大概有多少比例的處方,可能在病人自付費用方面受惠?另外,基於這項對病人的利益,你是否預期長期而言會對毛到淨(gross-to-net)的策略做任何重新思考?
Steven Basta - President, Chief Executive Officer, Director
Steven Basta - President, Chief Executive Officer, Director
So, Martin, thanks so much for the question. We're actually quite pleased with some of the initiatives that we've made on this Access First process. Although, as we commented in the prepared remarks, this is a gradual education process that's going to happen, again, office by office as we build confidence on the part of physicians. One element of it is the $0 copay initiative. So we have had since launch a copay support program that has. Brought down copays to $25, whether that was through retail pharmacies or through Blink. That copay support program and the copay card is... Available to any patient who has commercial insurance coverage that covers the product, but they might have a high copay. We're going to bring down the copay in most cases to that $25 level historically at retail pharmacies or at Blink. What we just did is we enhanced that program through Blink, so we'll bring down their copay all the way to zero. So if a patient has $100 copay on their insurance plan, we'll go ahead and buy that all the way down to zero. We cover. That incremental cost. That will obviously have a little bit of incremental patient support cost.
Martin,非常感謝你的問題。我們其實對於在這個 Access First 流程上所做的一些措施感到相當滿意。不過,正如我們在事先準備的發言中提到的,這是一個會逐步推進的教育過程,而且會再次以逐家診所的方式進行,因為我們要在醫師端建立信心。其中一個要素是 0 美元自付額($0 copay)措施。自上市以來,我們就有一個自付額補助計畫。不論是透過零售藥局或透過 Blink,都能把自付額降到 25 美元。該自付額補助計畫與自付額卡……適用於任何擁有商業保險、且其保險涵蓋本產品但自付額可能偏高的患者。在多數情況下,我們會把自付額降到過去在零售藥局或 Blink 的 25 美元水準。我們剛剛做的是透過 Blink 強化這個計畫,因此我們會把他們的自付額一路降到零。所以如果某位患者在其保險計畫下的自付額是 100 美元,我們會把它補貼到零。我們承擔。那部分的增量成本。這顯然會帶來一些額外的病患支持成本。
We already have a significant co-pay support program that's already built in.
我們本來就已經內建了一個相當可觀的自付額補助計畫。
I don't have a projection on the exact magnitude of that in terms of the percentage on our GTN, but it'll be a small impact.
我目前沒有對其在毛到淨(GTN)中所占百分比的精確預估,但影響會很小。
Sanjeev might have more insights on sort of the specific GTN impact, but on the eligibility, who's eligible for this? Is for commercial insured patients.
Sanjeev 可能對於具體的 GTN 影響有更多見解;但就資格而言,哪些人符合這項措施?是擁有商業保險的患者。
So we can't buy down the co-pay on government-insured patients, but for commercial-insured patients, where their plan covers Vequesna, we're going to buy down their co-pay. And the advantage of offering this through Blink is to encourage physicians and patients to adopt the use of Blink, where we have a much more robust communication with the physician and their staff to be able to support the prior authorization process, and it also changes. The decision architecture for the physician that instead of being concerned that even at $25 a month, $25 sounds innocuous, but over the course of a year, that can be $300 for a patient. That's a lot more than they would pay for a generic PPI that often costs them nothing. Now at $0 copay, it's a different decision. It costs your patient nothing either way, so which is the better drug for your patient? That changes that decision architecture.
因此,我們無法替政府保險患者降低自付額(co-pay),但對於商業保險患者,只要其保險計畫涵蓋 Vequesna,我們就會替他們降低自付額。而透過 Blink 提供這項方案的優勢在於,能鼓勵醫師與患者採用 Blink;在那裡我們能與醫師及其團隊進行更強而有力的溝通,以支援事前授權(prior authorization)流程,而且這也會改變。醫師的決策架構:與其擔心即便每月 25 美元,25 美元聽起來不痛不癢,但一年下來對患者可能是 300 美元。這比他們使用通常不需花錢的學名藥 PPI(質子幫浦抑制劑)要高得多。但若自付額為 0 美元,決策就不同了。不論哪種選擇,患者都不需要付費,那麼哪一個藥對患者更好?這就改變了那個決策架構。
And so it's for commercial patients. There is one state exclusion, by the way, just in full disclosure, Massachusetts has restrictions that prohibit us from having the differential copay, so it's not available to Massachusetts patients, but everyone else. Sanjeev, do you want to jump in on the GTN impact?
所以這是針對商業保險患者。順帶一提,完整揭露一下,有一個州被排除:麻薩諸塞州有相關限制,禁止我們採用差異化自付額,因此麻州患者無法使用,但其他州都可以。Sanjeev,你要補充一下 GTN(gross-to-net,毛額到淨額)影響嗎?
Sanjeev Narula - Chief Financial and Business Officer
Sanjeev Narula - Chief Financial and Business Officer
Yeah, to your point, so Marty, the GTN per se, obviously there's going to be minor impact, but it's insignificant when you look at the overall. Gross to net. But I think the way to think about it is it's going to be net positive for the company, even if we are paying a little bit higher because of $0 copay. But the contribution from each incremental script is going to be still positive.
好的,正如你所說,Marty,就 GTN 本身而言,顯然會有些微影響,但放在整體來看並不顯著。毛額到淨額。但我認為應該這樣看:即使因為 0 美元自付額而讓我們支付稍微多一點,對公司而言仍是淨正面。因為每一張新增處方(script)帶來的貢獻仍然是正的。
So net-net is a very positive thing for us as more patients come in and able to utilize this.
所以整體而言,隨著更多患者加入並能使用這項方案,對我們是非常正面的。
Martin Auster - Equity Analyst
Martin Auster - Equity Analyst
Excellent. Thanks. Thanks for the additional color. And I like the plan. See, there's nothing that feels better than walking the pharmacy and getting a free prescription. So I think it's smart.
很好。謝謝。謝謝你補充更多細節。我也喜歡這個計畫。你知道,沒有什麼比走進藥局拿到一張免費處方更讓人感覺好的了。所以我覺得這很聰明。
Steven Basta - President, Chief Executive Officer, Director
Steven Basta - President, Chief Executive Officer, Director
Thank you.
謝謝。
Operator
Operator
Thank you. Our next question or comment comes from the line of Umer Rafat from Evercore. Your line is open.
謝謝。我們下一個問題或意見來自 Evercore 的 Umer Rafat。您的線路已開通。
Mike DiFiore - Analyst
Mike DiFiore - Analyst
Hi, guys. This is Mike DiFiore in for Umer. Thanks so much for taking our questions. Just 2 for me.
嗨,各位好。我是 Mike DiFiore,代替 Umer 發問。非常感謝讓我們提問。我這邊只有兩個問題。
What are you seeing in 2027 payer negotiations that could change rebates or access, particularly if another PCAP launches?
你們在 2027 年的付款方(payer)談判中看到了哪些可能改變回扣(rebates)或可及性(access)的因素,特別是在另一個 PCAP 可能上市的情況下?
And second question is, does the inventory reserve explain most of the gross margin decline or are fulfillment costs putting recurring pressure on margins?
第二個問題是:存貨準備(inventory reserve)是否解釋了毛利率下滑的大部分原因?還是履約成本(fulfillment costs)正在對毛利率造成持續性的壓力?
Steven Basta - President, Chief Executive Officer, Director
Steven Basta - President, Chief Executive Officer, Director
Mike, thanks for the question. I'll take the first part and then the margin question I'll pass on to Sanjeev.
Mike,謝謝你的問題。第一部分我來回答,然後毛利率的問題我交給 Sanjeev。
From a payer negotiations perspective, our commercial insurance coverage is pretty broad under established contracts in many cases. And so in some cases, we contract with plans. In other cases, they're covering the product outside of our contract status. We've not seen any of that change in any meaningful way based upon the potential introduction. Of a second PCAP. So those negotiations aren't being altered at all by that dynamic. There are inevitably, here or there, specific plans that review processes over time, but nothing that constitutes a fundamental shift in any of our payer negotiations.
從付款方談判的角度來看,我們在商業保險的承保範圍相當廣,很多情況下都有既定合約。因此在某些情況下,我們與保險計畫簽約。在其他情況下,即使不在我們的合約狀態下,他們也會承保該產品。基於可能引入第二個 PCAP,我們並未看到任何有意義的變化。因此,這些談判完全沒有因為那個動態而被改變。當然,難免會有個別保險計畫隨時間進行流程審視,但沒有任何構成我們付款方談判的根本性轉變。
Sanjeev Narula - Chief Financial and Business Officer
Sanjeev Narula - Chief Financial and Business Officer
And just one other point, Steve. Yes, I take the second question, Mike, just adding on to the first point.
另外再補充一點,Steve。是的,Mike,第二個問題我來回答,也順便延伸第一點。
Mike, as there are always, puts and takes in gross to net.
Mike,毛額到淨額(gross-to-net)一向都有此消彼長的因素(puts and takes)。
We're also a growing company with that revenue growing up, so we have opportunities in terms of some of the other elements of gross to net, like distribution fees and all that. So as we become bigger, there's an opportunity to negotiate them down. So overall, we feel the trend that we have this year is comfortable and we don't expect any change due to a new competitor launching on that.
我們也是一家正在成長的公司,營收持續上升,因此在毛額到淨額的其他要素上也有機會,例如通路配送費(distribution fees)等等。隨著規模變大,我們有機會把這些費用談下來。所以整體而言,我們對今年的趨勢感到安心,也不預期因為新競品上市而出現任何變化。
On the point about your question on the gross margin, you're right. It's primarily the result of the one-time manufacturing charge that we took last quarter.
至於你問的毛利率問題,你說得沒錯。主要是因為我們上季認列了一次性的製造費用(one-time manufacturing charge)。
And we don't see any incremental pressure on the cost for distribution or anything like that. It's all very stable in line with our volumes.
我們沒有看到配送成本或其他方面有任何額外壓力。一切都非常穩定,且與我們的出貨量一致。
Mike DiFiore - Analyst
Mike DiFiore - Analyst
Great.
很好。
Thanks so much.
非常感謝。
Operator
Operator
Thank you. Our next question or comment comes from the line of Paul Choi from Goldman Sachs. Mr. Choi, your line is open.
謝謝。我們下一個問題或意見來自高盛(Goldman Sachs)的 Paul Choi。Choi 先生,您的線路已開通。
Paul Choi - Analyst
Paul Choi - Analyst
Hi.
嗨。
Thank you. Good morning, and thanks for taking our questions.
謝謝。早安,謝謝讓我們提問。
My first question is for Sanjeev. If we look at the guidance for the remainder of the year, it implies a revenue range of approximately $93 million to $108 million at the high end. Can you, given your comments on gross net expected to be at the lower end of the range, could you comment maybe on just what you think the drivers could be or factors that get you to the upper half of the implied guidance? And then I had a follow-up question.
我的第一個問題是問 Sanjeev。如果我們看今年剩餘期間的財測(guidance),它隱含的營收區間大約是 9,300 萬美元到高端的 1.08 億美元。考量你提到毛額到淨額(gross-to-net)預期會落在區間較低端,你能否評論一下,你認為有哪些驅動因素或條件能讓你們達到該隱含財測的上半部?然後我還有一個追問。
Sanjeev Narula - Chief Financial and Business Officer
Sanjeev Narula - Chief Financial and Business Officer
Sure.
當然。
Paul, I can't be more specific about my Q4 printer guidance than what we have been. I think you hit the nail.
Paul,關於第四季的更細部指引,我無法比我們目前已提供的內容更具體。我想你說到重點了。
We feel good about the momentum. Paul, the way to think about it is based on where the trends are, you saw the cover script growing 19% sequentially. We feel good about and the coverage first initiative, as Steve pointed out, beginning to show results. Obviously, it's going to take over a few quarters for us to see that. But I feel good about overall.
我們對動能感到樂觀。Paul,可以這樣理解:依照目前的趨勢,你看到覆蓋處方(covered script)季比成長 19%。我們對此感到有信心,而且如 Steve 所指出,「coverage first」倡議開始展現成果。當然,這需要幾個季度我們才會看得更清楚。但整體而言我感覺良好。
Momentum into that's why we were absolutely confident in reaffirming our guidance. And clearly, specifically, we'll announce the results when it comes in. Gross to net, think the way it kind of simply think about it is we've been fairly consistent in all three quarters, except maybe this quarter were a little bit lower, essentially because of the reason that I articulated on my call. As you have lower wholesale inventories.
這股延續的動能也是我們為何非常有信心重申財測。而且很明確地,等結果出來我們會公布。毛額到淨額方面,簡單來說,我們前三季基本上都相當一致,除了本季可能稍微低一些,主要是因為我在電話會議中闡述的原因:當批發端庫存較低時。
You actually end up with less pipeline cools, which actually reduces your ghost to net from that perspective.
你實際上會有較少的通路填充(pipeline fills),從那個角度看會降低你的毛額到淨額(gross-to-net)。
So if you normalize for that, our ghost to net is exactly what we've been seeing in the first two quarters.
所以如果把那個因素常態化,我們的毛額到淨額其實與前兩季看到的水準完全一致。
Typically in Q4, your ghost to net tends to be a little bit higher, primarily because of MDP. As the patients reach catastrophic coverage of $2,100, you ended up paying higher rebates.
通常在第四季,你的毛額到淨額會稍微高一些,主要是因為 MDP。當患者達到 2,100 美元的災難性給付(catastrophic coverage)門檻時,你最終需要支付更高的回扣。
So we expect that to happen. That's why, overall, I was comfortable saying it's going to be towards the lower part of that 55% to 59% of the range.
所以我們預期會發生這種情況。這也是為什麼整體而言,我可以有把握地說,它會落在 55% 到 59% 這個區間的較低端。
Paul Choi - Analyst
Paul Choi - Analyst
Okay, great.
好的,很好。
Thank you for that. And to follow-up on an earlier question, if another key cab does enter the U.S. Market next year, in terms of sort of historical pricing analogs. Do you expect sort of the pricing changes over the near to intermediate term to largely mirror what happened with the PPIs in terms of market pricing changes? Just any comments there would be helpful.
謝謝你的說明。再追問先前的一個問題:如果明年另一個 key cab 進入美國市場,從歷史定價類比(pricing analogs)的角度來看,你是否預期短期到中期的定價變化,大致會複製當年 PPI 市場的定價變化走勢?任何相關評論都會很有幫助。
Thank you.
謝謝。
Steven Basta - President, Chief Executive Officer, Director
Steven Basta - President, Chief Executive Officer, Director
I'm not sure we're in a position to project what's going to happen in terms of pricing impact in the market given that we haven't seen what the second entrant PCAB pricing might be or exactly what their strategies may be. So I'll pass on trying to forecast what changes might happen until we actually see them enter the market.
鑑於我們尚未看到第二家進入者的 PCAB 定價可能會是多少,或其策略究竟會是什麼,我不確定我們是否有條件去推估市場上定價影響將會如何發展。因此,在我們實際看到他們進入市場之前,我先不嘗試預測可能會發生哪些變化。
Paul Choi - Analyst
Paul Choi - Analyst
Great. Thanks, Steve.
很好。謝謝你,Steve。
Operator
Operator
Thank you. Our next question or comment comes from the line of Annabelle Samimy from Stifel.
謝謝。我們下一個提問或評論來自 Stifel 的 Annabelle Samimy。
Your line is now open, ma'am.
女士,您的線路已開通。
Annabel Samimy - Equity Analyst
Annabel Samimy - Equity Analyst
Hi, thanks for taking my question.
嗨,謝謝讓我提問。
So a few here. So first on the efforts for increasing BlinkRx, I guess in terms of getting past these frictions, where do you see the most resistance from physicians for adoption of Blink?
我這裡有幾個問題。首先關於提升 BlinkRx 的推動工作,我想就克服這些摩擦而言,您認為醫師在採用 Blink 上最大的阻力會在哪裡?
Because from an economic perspective for the patient, it seems to be a very easy decision. So is it lack of awareness or is it patient willingness to use? I've heard from some KOLs that patients, some of their patients are just very comfortable with their local pharmacies and they don't, really want to use Blink. So is it resistance from the physician side or patient side? And is there a level of.
因為從病患的經濟角度來看,這似乎是一個很容易的決定。所以是缺乏認知,還是病患不願意使用?我聽一些 KOL 說,有些病患對他們在地藥局非常習慣,因此不太想用 Blink。所以阻力是在醫師端還是病患端?以及是否存在某種程度的。
I guess, a percent level of prescriptions that you expect would go through Blink at a steady state, and could that in the future have an impact on GrossNet, or is it going to be primarily the support that you're providing through Blink as opposed to just Blink itself?
我想問的是,從長期穩態來看,您預期會有多少比例的處方會透過 Blink?而這在未來是否可能影響 GrossNet,或者主要會是您透過 Blink 提供的支援(而不只是 Blink 本身)所帶來的影響?
And then I guess last question, not specifically related to the.
然後我想最後一個問題,並非特別與。
Litigation with FDA, but I was hoping you can be a little bit more explicit about the extent to which some of your new studies might, I guess, facilitate more IP aside from just the pediatric exclusivity. So maybe you can talk to us about that a little bit. Thanks.
與 FDA 的訴訟相關,但我希望您能更明確說明:您的一些新研究在多大程度上可能有助於取得更多 IP(智慧財產權)保護,而不僅僅是兒科獨占期。所以也許您可以跟我們談談這部分。謝謝。
Steven Basta - President, Chief Executive Officer, Director
Steven Basta - President, Chief Executive Officer, Director
Terrific, Annabel.
太好了,Annabel。
Thank you for each of the parts of that.
謝謝你把問題拆成幾個部分來問。
So first on sort of the efforts of getting prescriptions to blink, I don't view that there is anything I would describe as resistance. It's more that there's inertia.
首先,關於把處方導向 Blink 的推動工作,我不認為有任何我會稱之為「阻力」的情況。更多的是「慣性」。
And so what the inertia looks like is physicians just have a habit of prescribing to the patient's local pharmacy because that pharmacy is in the patient's records in the EHR, and they simply ask the patient, where do you want your prescriptions to go? And they might be prescribing three different drugs, and they send them all to CVS down the street. And so what we're trying to do is simply overcome that inertia and sort of the path of least resistance perception on the part of physician, if I just prescribe this where I prescribe everything else. And teach them that it's a meaningfully better experience for their patient and a better experience for their staff with a higher likelihood their patient's going to get the product if they prescribe to Blink. So, it doesn't take long. It takes ten seconds for the physician to find BlinkRx in their EHR and prescribe to BlinkRx. It might take thirty seconds for them to have a conversation with the patient about why they want to go through a mail-order pharmacy because it improves their ability to get the product and it's going to improve their out-of. That's candidly one of the advantages of offering the $0 copay program is that it makes that conversation from the physician to the patient an easier conversation of, I'm going to send this to a mail-order pharmacy because that's the only place where you're going to be able to get this product at zero cost if it gets covered by your insurance plan. So it changes the willingness of a patient to get a drug through a mail-order pharmacy rather than just to get it through the retail pharmacy down the street. So it's.
這種慣性表現為:醫師習慣把處方開到病患的在地藥局,因為該藥局已經在 EHR 的病患資料裡,醫師只是問病患「你希望處方送到哪裡?」而且他們可能同時開三種不同的藥,然後全部送到街角那家 CVS。所以我們要做的,就是克服這種慣性,以及醫師端「最省事路徑」的認知:我就把它開到我平常所有處方都開去的地方。並教育他們:若開到 Blink,對病患而言是明顯更好的體驗,對診所人員而言也是更好的體驗,而且病患更有可能真正拿到產品。所以,其實不需要很久。醫師在 EHR 裡找到 BlinkRx 並把處方開到 BlinkRx,只要 10 秒。他們可能需要 30 秒跟病患解釋為什麼要透過郵寄藥局,因為這能提升取得產品的能力,並且會改善他們的自付額(out-of-)。坦白說,提供 0 美元自付額($0 copay)方案的優勢之一,就是讓醫師對病患的這段對話更容易:我會把處方送到郵寄藥局,因為如果你的保險計畫涵蓋,只有那裡你才能以零成本取得這個產品。因此,這會改變病患透過郵寄藥局取藥的意願,而不是只想在街角的零售藥局取藥。所以這是。
I don't think there's active resistance anywhere. Nobody's objecting, saying, oh, I really don't want to do that. But there is inertia. Patients are just comfortable getting their drug at their CVS or Walgreens down the street, and physicians are just comfortable by default prescribing it to the local pharmacy. So we have to teach the physician why it's better for their patient, why it's better for their staff, and then they might have to take thirty seconds and have a conversation with their patient on why they're sending it to this other pharmacy. Once that process happens, once they become familiar with that.
我不認為任何地方存在主動的阻力。沒有人會反對說:「喔,我真的不想這麼做。」但確實存在慣性。病患只是習慣在街角的 CVS 或 Walgreens 取藥,而醫師也只是習慣預設把處方開到在地藥局。所以我們必須教育醫師:為什麼這對病患更好、為什麼對他們的工作人員更好;然後他們可能需要花 30 秒跟病患說明為什麼要送到另一家藥局。一旦這個流程跑過、他們熟悉之後。
Just a second nature kind of conversation. So what we have to do is teach the physician to have that conversation the first five times, 10 times, until it becomes second nature for them that they just have a really simple conversation with their patient. You know what? This is where I send this drug because they're going to be able to provide you really great support. And then it's really quick. So we're not actually seeing anything we would describe as resistance, but rather just inertia, and we're changing long-standing habits. And that takes multiple sales calls and it takes multiple rounds of reinforcement.
這就會變成一種下意識的對話。所以我們要做的是,教醫師在前五次、十次時先把這段對話講順,直到對他們而言變成自然而然:只要跟病患做一段非常簡單的說明。你知道嗎?這個藥我會送到這裡,因為他們能提供你非常好的支援。然後就會很快。因此,我們其實沒有看到任何可稱為「阻力」的情況,而是慣性;我們正在改變長期形成的習慣。而這需要多次業務拜訪,也需要多輪強化。
We haven't on your second point of is there a level of prescriptions that would go through blank? That's going to vary on a regional basis. There are some regions where Medicaid patients, for example, need to go through local pharmacies because of certain state rules. There are a number of different dynamics in different regions, but our intention is to drive more and more prescriptions to blank and increase the rates. I think we'll better visibility over the next several quarters as to what. Is the magnitude of scripts going to blink and sort of percentage that's achievable at this point. Every incremental gain helps our access perception and helps our access reality. So it both makes the.
至於你第二點:是否存在一個會透過 Blink 的處方比例水準?這會因地區而異。例如在某些地區,Medicaid 病患因為某些州的規定,必須透過在地藥局。不同地區有許多不同的動態因素,但我們的目標是把越來越多處方導向 Blink,並提高比例。我想在接下來幾個季度,我們會更清楚看到。處方導向 Blink 的量級,以及目前可達成的比例大概是多少。每一個增量的提升都能幫助我們在可近性(access)的認知與實際可近性。因此,這兩者都會讓。
Drug easier to get and improves physician perception on how easy the drug is to get, which will improve physician prescribing behavior. So both of those are factors that flow into the positive reinforcement.
藥品更容易取得,並改善醫師對「這個藥有多容易取得」的觀感,進而提升醫師的開立行為。所以這兩者都會形成正向回饋的一部分。
On your last question regarding the extent to which some of our new studies could facilitate more IP, we are certainly looking at strategies that could potentially enhance the IP duration. The current studies. Other than the EOE study are not specifically intended for IP extension strategies. So the as needed study is not about extending IP, but rather expanding the market. There is a significant population of patients who are regularly and frequently talking to their physician about whether or not there's an alternative for them other than daily PPI therapy because you can just go on the internet and see. The noise around chronic PPIs and whether or not you want to be on a PPI chronically, but if you've got chronic reflux symptoms and painful heartburn, you can't get off of your daily PPI, but you really want to get off of the daily therapy, that's our opportunity with the as-needed use protocol with that.
至於你最後一個問題:我們的一些新研究在多大程度上可能促進更多 IP,我們確實正在評估一些策略,可能有助於延長 IP 的存續期間。目前的研究。除了 EOE 研究之外,並非特別為了 IP 延展策略而設計。因此,按需(as needed)研究的目的不是延長 IP,而是擴大市場。有相當多的病患會經常、頻繁地和醫師討論:是否有除了每日 PPI 治療以外的替代方案,因為你上網就能看到。關於長期使用 PPI 的各種雜音,以及你是否想要長期使用 PPI;但如果你有慢性逆流症狀與疼痛性的胃灼熱,你又無法停用每日 PPI,但你真的想停止每日治療,這就是我們在按需使用方案上的機會。
Dosing regimen approved in a couple of years, we would open up a very different conversation with physicians about solving the needs for patients who are coming and asking them specifically about whether or not there's an as-needed use option. So that's really a market expansion study, not a life cycle extension study. The EOE study is specifically intended to support an extension of our exclusivity in addition to expanding the population of patients who receive the product. So there's obviously an unmet need.
如果在幾年後這個給藥方案(dosing regimen)獲得核准,我們就能與醫師展開一段非常不同的對話,來解決那些前來詢問、並且明確問「是否有按需使用選項」的病患需求。所以這確實是一項市場擴張研究,而不是產品生命週期延展研究。EOE 研究則是明確用來支持在擴大用藥病患族群之外,進一步延長我們的獨占期。因此,顯然存在未被滿足的需求。
In EOE to understand the magnitude of clinical benefit that a patient can get from acid suppression therapies. We're doing the first large well-controlled trial of acid suppression in EOE and we'll that data in the coming months. We'll that data this quarter from the first 12-week blinded portion of that study.
在 EOE 中,以了解患者可從抑酸治療中獲得的臨床效益幅度。我們正在進行首個大型、良好對照的 EOE 抑酸治療試驗,並將在未來幾個月內取得該數據。我們將在本季公布該研究第一個 12 週盲法階段的數據。
And if that study is successful in addition to... Leading to a phase 3 study that could expand our use into that population of patients and serve the needs of those patients, it has the additional advantage of potentially opening up a conversation with FDA about a written request for the pediatric exclusivity extension.
而如果該研究成功,除了……可推進至第三期研究、將我們的使用範圍擴展到該患者族群並滿足其需求之外,還有一項額外優勢:可能開啟與 FDA 就兒科獨占期延長之書面請求(written request)進行討論的機會。
Annabel Samimy - Equity Analyst
Annabel Samimy - Equity Analyst
Okay, great, thank you.
好的,很棒,謝謝。
Steven Basta - President, Chief Executive Officer, Director
Steven Basta - President, Chief Executive Officer, Director
And then I think you also had a question about GTN via Blink, is that correct?
然後我想你也有一個關於透過 Blink 的 GTN 的問題,對嗎?
Sanjeev Narula - Chief Financial and Business Officer
Sanjeev Narula - Chief Financial and Business Officer
Yes, correct, not through Blink. Yes. So, Annabel, the way simple to think about it is overall, it's actually a good thing and positive for the company and the patient.
是的,沒錯,不是透過 Blink。是的。所以,Annabel,用最簡單的方式來看,整體而言這其實是對公司和患者都有利的好事。
So once you, as we pointed out earlier, the additional $25 actually is going to be more than offset by the incremental script contribution that we would get from each of the script that is going through Blink that earlier was not able to get fulfilled. So I don't expect any change in ghost to net because of scripts going to a Blink. The other thing overall if you think about it is.
因此一旦你——如我們先前指出的——額外的 25 美元實際上會被每張經由 Blink 流轉、而先前無法完成配藥的處方所帶來的增量處方貢獻所抵銷,甚至超過。所以我不預期因為處方轉到 Blink 而使 gross-to-net 有任何變化。另外,整體來看,如果你這樣思考的話。
Blink refill rates are much better. So overall, that's a good thing for, again, patients and the company as more scripts go towards Blink.
Blink 的續配率(refill rates)好很多。所以整體而言,隨著更多處方轉向 Blink,這對患者和公司來說同樣都是好事。
Annabel Samimy - Equity Analyst
Annabel Samimy - Equity Analyst
Okay, perfect.
好的,完美。
Thank you.
謝謝。
Operator
Operator
Thank you. Our next question or comment comes from the line of Joseph Stringer from Needham and Company. Mr. Stringer, your line is now open.
謝謝。我們下一個提問或評論來自 Needham and Company 的 Joseph Stringer。Stringer 先生,您的線路已開通。
Joseph Stringer - Analyst
Joseph Stringer - Analyst
Hi, thanks for taking our question. Just to follow-up on the Phase 2 EOE trial, we understand part of its goal is to secure pediatric extension, but could you just level set us on what a successful Phase 2 signal looks like here this quarter? And if those results are favorable, what are the next steps and expected timelines towards securing that extension?
嗨,謝謝讓我們提問。就第二期 EOE 試驗追問一下,我們理解其部分目標是爭取兒科延長,但您能否幫我們校準一下:本季在這裡所謂成功的第二期訊號看起來會是什麼?如果結果正面,接下來的步驟以及取得該延長的預期時程會是什麼?
Thank you.
謝謝。
Steven Basta - President, Chief Executive Officer, Director
Steven Basta - President, Chief Executive Officer, Director
So, Jess, thanks so much for the question. So just a quick synopsis of the EOE study design.
好的,Jess,非常感謝你的問題。我先快速概述一下這項 EOE 研究的設計。
There are two phases in this trial. There's the first 12-week blinded treatment phase. So patients were randomized to receive either Vaquesna or placebo on a blinded randomized basis. That data we will be reporting this quarter.
這個試驗有兩個階段。第一個是 12 週的盲法治療階段。因此患者以盲法隨機分派方式接受 Vaquesna 或安慰劑。我們將在本季報告該數據。
So the patients have completed that 12-week treatment period and all that data is being aggregated and analyzed. Over time.
因此患者已完成該 12 週治療期,所有數據正在彙整與分析中。隨著時間推進。
And so that'll be coming in the next couple of months. The patients are continuing on therapy for an additional 12 weeks. So we will have a full 24 weeks of treatment, but that continuation therapy is on an open-label basis. So that will be available toward the latter part of Q1. And at that point, when we've got that data aggregated, we'll be having a conversation with FDA about whether or not the data collectively.
因此在接下來幾個月內就會出來。患者將繼續治療額外 12 週。所以我們將有完整 24 週的治療數據,但延伸治療是以開放標籤(open-label)方式進行。因此該部分將在第一季後段可取得。屆時,當我們把數據彙整完成後,我們將與 FDA 討論,整體數據是否。
Provides a clear path to phase three clinical trials. What would those phase three trials look like? Is it appropriate to include pediatric patients in those trials? And would they like to issue a written request for us to include pediatric patients, which would then qualify us for the six-month pediatric exclusivity extension if we complete that study in accordance with the agreement with FDA? So those conversations with FDA would happen in 2027. Obviously, that's predicated upon what the results in the study are. The primary. Endpoint in the study is a reduction of eosinophil counts.
提供一條清晰的路徑進入第三期臨床試驗。那些第三期試驗會長什麼樣子?是否適合在那些試驗中納入兒科患者?以及他們是否願意發出書面請求,要求我們納入兒科患者;若我們依照與 FDA 的協議完成該研究,便可符合取得 6 個月兒科獨占期延長的資格。因此,與 FDA 的這些對話會在 2027 年進行。當然,這取決於研究結果如何。本研究的主要。終點是降低嗜酸性球計數。
So, it's a primarily histological endpoint. We have secondary endpoints in the study to look at symptom improvement.
所以這主要是一個組織學(histological)終點。我們也有次要終點,用來觀察症狀改善。
Based upon the aggregate of that data, both the histologic improvement and the symptom improvement, we will assess what we believe the prospects are for doing a Phase 3 study and what a Phase 3 study would look like, and then we'll the conversations next year with FDA.
基於這些彙總數據——包括組織學改善與症狀改善——我們將評估我們認為進行第三期研究的前景,以及第三期研究應該如何設計,然後我們將在明年與 FDA 進行相關對話。
At the conclusion of those. If we're in agreement with FDA on the July and the phase three studies, we would start those phase three trials. But those conversations will happen in 27 and it'll take, so we'll be reporting before the end of this year, the first 12-week data, then by the end of Q1 we'll the second 12-week data, so the full 24-week treatment period, the second 12 weeks being the open label portion.
在那些對話結束時。如果我們與 FDA 就時程以及第三期研究達成一致,我們就會啟動那些第三期試驗。但那些對話會在 27 年進行,而且需要——因此我們會在今年底前報告第一個 12 週數據,然後在第一季底前公布第二個 12 週數據,也就是完整 24 週治療期的數據,其中後 12 週為開放標籤部分。
Joseph Stringer - Analyst
Joseph Stringer - Analyst
Thank you.
謝謝。
Operator
Operator
Our next question or comment comes from the line of Yatin Suneja from Guggenheim. Your line is now open.
我們下一個提問或評論來自 Guggenheim 的 Yatin Suneja。您的線路已開通。
Yatin Suneja - Equity Analyst
Yatin Suneja - Equity Analyst
Guys, thank you for taking my questions. I have two quick questions. So the first one is, as we think about sort of revenues ramping up or revenues increasing in 2027, how much of the incremental build out will come on the commercial side? If you can maybe just comment on that.
各位,謝謝回答我的問題。我有兩個簡短問題。第一個是,當我們思考 2027 年營收爬坡或營收增加時,增量擴編中有多少會來自商業端?如果可以的話,請簡單評論一下。
And then the second one is just on, maybe business development, right? You are now generating operating cash flow, which is positive. How do you think about bringing in asset? What type of asset, if at all? What is your affordability look like as you sort of build the company beyond the question?
第二個是關於——也許是商務拓展(business development),對吧?你們現在正在產生正向的營運現金流。你們如何看待引進資產?如果要引進的話,會是什麼類型的資產?當你們在把公司擴展到超越目前這個問題時,你們的可負擔能力(affordability)會是什麼樣子?
Thank you.
謝謝。
Steven Basta - President, Chief Executive Officer, Director
Steven Basta - President, Chief Executive Officer, Director
Yeah, and thank you for both of those. I appreciate the opportunity to start giving some sense of how we're thinking about the organization. Obviously, we're not providing 2027 financial guidance today, so I don't want to get into exactly what the operating expenses will be, but we don't see a fundamental change in the commercial infrastructure cost for next year. Our sales force is well established. Our marketing programs are in place. We are doing the things that we need. Need to do to influence physicians. So as we continue to grow revenue next year, we're expecting that the commercial organization and the commercial spend is largely in line with how we're approaching this year, although I would caveat that with we're not yet providing financial guidance for next year. So we'll do that when we get to the call in January or February.
是的,也謝謝你這兩個問題。我很感謝有機會開始分享我們如何思考組織配置。顯然,我們今天不提供 2027 年財務指引,所以我不想深入到營運費用會是多少的細節,但我們不認為明年商業基礎建設成本會有根本性的變化。我們的銷售團隊已相當成熟。我們的行銷計畫也已到位。我們正在做我們需要做的事情。需要做的事,以影響醫師。因此,隨著我們明年持續成長營收,我們預期商業組織與商業支出大致會與我們今年的做法一致;不過我要補充的是,我們尚未提供明年的財務指引。我們會在一月或二月的電話會議時提供。
And Sanjeev may have any additional insights in that process.
而 Sanjeev 可能也會在這個過程中補充一些額外見解。
I'll just quickly take the second part of that and then turn. To Sanjeev for any other insights on that. The second part of your question on sort of how we're thinking about business development, as we've said in previous conversations, and in conversations with many of our investors, our intent is to build a significant GI business. So, Loquesna gives us an enormous foothold in the gastroenterology community because of the breadth of. Of application of a new reflux treatment to patients that physicians are seeing every day. We're getting time and attention with gastroenterologists. We're building really solid relationships throughout our sales organization within the medical education teams, etc. We're building really deep relationships with gastroenterologists. That's leverageable for future products, and we are starting the process of identifying what the future products would be that we would bring in. Our expectation is over the coming years, we bring in additional GI products. It could be commercial products. It could be phase two clinical programs that then need to complete phase three to launch. But the intention would be that they would be products that we could launch before 2033 potential exclusivity loss. So we've got the next six years to complete development and launch those programs to build out a significant GI portfolio. So you should expect in the coming years to see one or. More deals to bring in additional assets. We're not projecting exactly when that happens. Depends on when we find the right assets and come to the right terms.
我先快速回應問題的第二部分,然後再轉給Sanjeev,看看他是否還有其他補充。關於你提到的第二個問題,也就是我們如何思考商務拓展(business development),正如我們在先前的對話以及與許多投資人交流時所說,我們的意圖是建立一個具規模的腸胃科(GI)業務。因此,Loquesna 讓我們在腸胃科社群中取得非常重要的立足點,因為這項新的胃食道逆流治療在臨床上的適用範圍很廣,涵蓋了醫師每天都會看到的病人。我們正在獲得腸胃科醫師的時間與關注。我們在整個銷售組織、醫學教育團隊等方面建立非常穩固的關係。我們正在與腸胃科醫師建立非常深厚的關係。這些關係可作為未來產品的槓桿,而我們也已開始辨識未來可能導入的產品。我們預期在未來幾年會引進更多GI產品。可能是已商業化的產品。也可能是第二期臨床計畫,之後需要完成第三期才能上市。但我們的意圖是,這些產品應該能在2033年可能面臨專屬權到期之前完成上市。因此我們接下來大約有六年的時間,完成開發並推出這些計畫,以建立具規模的GI產品組合。所以你應該會在未來幾年看到一筆或多筆交易,引進額外資產。我們不會精確預測何時發生,這取決於我們何時找到合適的資產並談到合適的條件。
Sanjeev Narula - Chief Financial and Business Officer
Sanjeev Narula - Chief Financial and Business Officer
Yeah, so Steve, just adding to, I think both the questions you asked, and I think the simple way to think about 2027 revenue, again, we're not giving the guidance, will grow faster than our operating expenses. And that's the leverage that will drive consistent on a full year basis.
是的,Steve,我補充一下你剛才問的兩個問題。我認為看待2027年營收最簡單的方式是:我們雖然不提供指引,但營收成長會快於營運費用的成長。而這種槓桿效應將在全年基礎上推動公司持續地……
Positive cash flow for the company. And you saw that last couple of quarters, we kind of demonstrated that. Again, it's going to continue that journey with moderate growth in operating expenses, but clearly significant growth in the top-line. So I think that's there. That then start to create capacity. Your question also was in terms of business development capacity. So we will start to begin having some capacity obviously. We're mindful of our obligations, we start paying back some of our turnout in 2028.
為公司帶來正向現金流。你也看到過去幾個季度我們某種程度上已經展現了這點。接下來仍會延續這個軌跡:營運費用溫和成長,但營收端(top-line)會有明顯成長。所以我認為這點是存在的。接著就會開始創造出一些容量(capacity)。你也問到商務拓展的容量。因此我們顯然會開始具備一些容量。同時我們也會留意自身的義務,我們在2028年開始償還部分我們的……
We got to make sure the cash flow is there, and we will have plenty of cash flow for that and to meet our obligations in terms of liquidity hold on reform and start investing in business development. So that's the pivot point that 2027 will start to bring in terms of start investing in business development.
我們必須確保現金流到位;而我們將有充足的現金流來做到這點,並在流動性方面滿足我們的義務、維持……,同時開始投入商務拓展。因此,2027年將是開始投入商務拓展的轉折點。
Operator
Operator
Thank you. Our next question or comment comes from the line of Dennis Ding from Jefferies. Mr. Ding, your line is now open.
謝謝。下一位提問或評論來自Jefferies的Dennis Ding。Ding先生,您的線路已開通。
Dennis Ding - Analyst
Dennis Ding - Analyst
Hey, good morning. Thanks for taking our questions. We have two.
嗨,早安。謝謝你們回答我們的問題。我們有兩個問題。
Number one, so the competitor PCAP that may be approved in January, when I look at market comps, it feels like LDL lowering drugs might be a decent proxy since it's a heavily genericized market and branded drugs are positioned in late line and when we look at the launch of Lafendra.
第一,可能在一月獲批的競品PCAB,當我看市場可比案例時,感覺降LDL藥物可能是個不錯的類比,因為那是一個高度學名藥化的市場,而品牌藥通常定位在較後線(late line)。當我們看Lafendra的上市時……
That was actually a slight tailwind to existing branded drugs. Do you agree with that? And are there other analogs you can point us to help us get confidence that a new player wouldn't slow your own growth? And then question number two, for 2027, I see consensus at 495, which implies a pretty meaningful acceleration.
那其實對既有品牌藥帶來了些微的順風(tailwind)。你同意這個看法嗎?另外,還有沒有其他你們可以指出的類比案例,來幫助我們更有信心:新進競爭者不會拖慢你們自身的成長?第二個問題,關於2027年,我看到市場共識是4.95億,這意味著相當明顯的加速成長。
You've also previously talked about reemphasizing the PCP call point at some point. So are you planning. To do that in 2027 or what do you need to see exactly to put additional resources into that call point?
你們之前也談到在某個時間點會重新強調對PCP(基層照護醫師)的拜訪重點(call point)。所以你們是否計畫在2027年這麼做?或者你們需要看到哪些具體條件,才會把更多資源投入到這個拜訪重點上?
Thank you.
謝謝。
Steven Basta - President, Chief Executive Officer, Director
Steven Basta - President, Chief Executive Officer, Director
Thanks so much for the insights and thank you for sharing with the group the context of the fact that a second entrant into a market does in fact expand physician awareness and expand the category. We fully expect that that's going to be the case in the context of the acid reflux market and how one thinks about the introduction of a second GCAB.
非常感謝你的洞見,也謝謝你向大家分享這個背景:市場出現第二個進入者,確實會提升醫師認知並擴大品類。我們完全預期在胃酸逆流市場、以及引入第二個GCAB時,也會是同樣的情況。
We certainly anticipate that having two sales forces. Calling on physicians, telling them that they should be thinking about using PCABs for their patients who are failing on prior PPI therapy will expand awareness. And it'll just change the mindset that instead of sort of thinking about Bequezna as a new product and what do I need to do as a new product, if there are multiple products in a category, suddenly physicians think about, well, when am I going to adopt a new category? And then as they think about that, our product has three years of history, lots of established relationships, lots of established use. With patients, their colleagues are comfortable with the product. So a physician beginning to use PCABS is going to be much more inclined to use the market-leading product. And a physician who's already got experience with Vequesna has already heard from their patients how much better they feel on this product is going to be much more inclined to use the product with which they already have comfort. So I think the scenario you're describing is exactly what we would expect that happen, which is the second product entrant actually shifts much more awareness to. The need to take patients to the new class of products and the market leader benefits along with the introduction of the second product. So I do think it's going to create a tailwind and we're looking forward to the impact that that's going to have. On the second part of your question regarding the emphasis on PCPs, our priority is in GI and will remain in GI. We're not expecting that to change in 2027. So we're making 70%. Plus for sales calls on gastroenterologists and I would fully expect that remains the core focus through 2027. We are really thinking about how do we build the confidence in the gastroenterology community. They already have confidence in how effective this product is, and they already have confidence that this product can be life-changing for many of their patients, but how we build the confidence that it's easy to get for their patients can get it affordably, that when their patients stay on it, they have a really good long-term experience that.
我們確實預期,當有兩支銷售團隊拜訪醫師、告訴他們應該考慮讓先前PPI治療失敗的病人使用PCAB時,將會提升市場認知。這也會改變思維:不再只是把Bequezna視為一個新產品、思考「面對新產品我需要做什麼」,而是當一個品類裡有多個產品時,醫師會開始思考「我什麼時候要採用一個新的品類?」而在他們思考這件事時,我們的產品已有三年的歷史、許多既有關係、許多既有使用經驗。病人方面的使用也已建立起來,他們的同儕對這個產品也很熟悉。因此,一位剛開始使用PCAB的醫師,會更傾向使用市場領先的產品。而一位已經有Vequesna使用經驗的醫師,已經從病人口中聽到使用這個產品後感覺好很多,也會更傾向使用他們已經熟悉的產品。所以我認為你描述的情境正是我們所預期會發生的:第二個產品進入者其實會大幅提升對……將病人轉換到新藥物類別的需求認知,而市場領導者會在第二個產品導入時一同受益。因此我確實認為這會帶來順風,我們也期待它將帶來的影響。至於你第二部分關於強調PCP的問題,我們的優先順序在GI,且仍將以GI為主。我們不預期2027年會改變。因此,我們目前約70%……以上的銷售拜訪都聚焦在腸胃科醫師,我完全預期到2027年這仍會是核心重點。我們真正思考的是:如何在腸胃科社群中建立信心。他們已經對這個產品的療效有信心,也已經相信這個產品能為許多病人帶來改變人生的效果,但我們要如何建立信心,讓他們覺得病人取得藥物很容易、能以可負擔的方式取得,而且當病人長期使用時,會有非常好的長期體驗,這……
Repetition of those conversations with physicians through multiple calls deepens our relationships in GI, and that's the core focus through 2027.
透過多次拜訪與醫師重複進行這些對話,會加深我們在GI領域的關係,而這將是到2027年的核心重點。
There will come a time when we expand into more primary care adoption, but I don't envision that in the near term. I think our core selling strategy remains for the foreseeable future.
未來會有某個時間點,我們會擴大到更多基層照護端的採用,但我不認為短期內會發生。我認為在可預見的未來,我們的核心銷售策略仍會維持不變。
Dennis Ding - Analyst
Dennis Ding - Analyst
Perfect.
很好。
Thank you.
謝謝。
Operator
Operator
Thank you. Our next question or comment comes from the line of Matthew Caulfield from HC Wainwright and Company. Your line is now open, sir.
謝謝。下一位提問或評論來自HC Wainwright and Company的Matthew Caulfield。先生,您的線路已開通。
Matthew Caufield - Equity Analyst
Matthew Caufield - Equity Analyst
Great. Hi, good morning, Steve, Sanjeev and team.
很好。嗨,早安,Steve、Sanjeev 以及團隊。
Regarding the discussed 65% total quarterly prescriptions being covered prescriptions, are those Rx completely covered or could those patients be paying the partial 25% or $25 rate with partial coverage? And has that split continued to improve between full coverage. And the possible partial coverage.
關於先前討論到每季總處方量中有 65% 為「有給付的處方」,這些 Rx 是完全給付嗎?還是說其中部分病患可能是在部分給付下,仍需自付 25% 或每張處方 25 美元的費率?另外,在「完全給付」與「可能的部分給付」之間的占比,是否持續改善?
Thanks for any color there on the coverage discussion.
若能就給付覆蓋的討論補充一些說明,感謝。
Steven Basta - President, Chief Executive Officer, Director
Steven Basta - President, Chief Executive Officer, Director
So, Matthew, I'll start the answer to this and Sanjeev might have more insights and add more to this.
Matthew,我先回答這個問題,Sanjeev 可能會有更多洞見並補充。
And so, when we think about coverage, there really are different categories of patients who will experience different out-of-pocket costs. And so.
我們在思考給付覆蓋時,實際上病患會落在不同類別,因此自付額(out-of-pocket)也會不同。所以。
The out-of-pocket cost for commercial insured patients whose commercial plans cover Boquesna, that's where we can apply our copay programs, whether it's the copay program that buys down the cost for the patient to $25 in a retail pharmacy or the same copay program with the enhancement that we can buy down their cost to $0 if the prescription goes through Blink. That's really a copay buy down that we can offer to a commercially insured patient. And that's very typical in the industry. You see that with any number of companies through this process. That can make the cost of the patient effectively zero in many cases and can broaden the awareness and the availability of this product for a significant number of commercially insured patients. We're not able to offer the same sort of copay support programs for government insured patients. And so the copay experience for a government insured patient may vary depending upon. The Medicare Part D plan that they're on, whether or not it covers the product, whether or not they have a copay associated with that plan, whether or not they've hit the $2,100 cap, so they may have no copay associated with that. Branded drug or any drug that's dispensed once they've hit the cap. Also, low-income subsidy patients or Medicaid patients may have a very low out-of-pocket cost. So the copay experience just varies by patient depending upon patient categories.
對於商業保險病患,若其商業保險方案涵蓋 Boquesna,我們就能套用自付額補助(copay)方案:不論是把病患在零售藥局的自付成本降到 25 美元的 copay 方案,或是同一套 copay 方案再加強,讓處方若透過 Blink 流轉時可把自付成本降到 0 美元。這本質上就是我們能提供給商業保險病患的 copay 降付(buy down)。這在產業中非常常見。你會在許多公司看到類似作法。在很多情況下,這能讓病患的實際成本接近於零,並能提升相當多商業保險病患對此產品的認知與可近性。但對於政府保險病患,我們無法提供同樣類型的 copay 支援方案。因此,政府保險病患的 copay 體驗可能會因為不同因素而有所差異。例如他們所參加的 Medicare Part D 計畫、該計畫是否涵蓋此產品、該計畫是否有 copay、以及他們是否已達到 2,100 美元的上限;一旦達到上限,無論是品牌藥或任何藥品在給付後可能就不再有 copay。此外,低收入補助(low-income subsidy)病患或 Medicaid 病患的自付額也可能非常低。所以,copay 體驗會依病患類別而有所不同。
Sanjeev, I don't know if there's more that you want to add to that process.
Sanjeev,我不確定你是否還想就這個流程再補充一些?
Sanjeev Narula - Chief Financial and Business Officer
Sanjeev Narula - Chief Financial and Business Officer
Yeah, just one quick comment. Overall.
是的,我補充一點簡短的評論。整體而言。
If you, Matthew, look at the impact, the gross to net, the impact is insignificant with the additional $25 that now we offer a $0 copay in terms of our gross to net because we're already covering a lot of the buy down as part of our gross to net. I think the important thing to note there is we believe we will get incremental scripts.
Matthew,如果你看其影響,從毛額到淨額(gross-to-net)的角度來看,新增的 25 美元、以及我們現在提供 0 美元 copay,對我們的 gross-to-net 影響其實不顯著,因為我們本來就在 gross-to-net 中承擔了相當多的降付(buy down)。我認為重點是,我們相信會因此帶來增量處方量(incremental scripts)。
Through the $0 copay, and that will more than offset any incremental cost that we believe will be insignificant in the scheme of things from a gross net perspective.
透過 0 美元 copay 帶來的增量處方,將足以抵消我們認為在 gross-to-net 角度下、整體而言不顯著的任何額外成本。
Matthew Caufield - Equity Analyst
Matthew Caufield - Equity Analyst
Okay, it's helpful. I appreciate it. Thanks.
好的,這很有幫助。感謝說明。謝謝。
Thank you.
謝謝你。
Operator
Operator
Our next question or comment comes from the line of Chase Knickerbocker from Craig Hallow. Your line is now open, sir.
下一個提問或評論來自 Craig Hallow 的 Chase Knickerbocker。先生,您的線路已開通。
Chase Knickerbocker - Analyst
Chase Knickerbocker - Analyst
Good morning. Congrats on the progress here. Just a couple for me. I'm going to ask another one on the access side, but maybe just a little bit more metric-focused.
早安。恭喜你們在這裡取得進展。我有幾個問題。我會再問一個關於可近性(access)的問題,但可能更偏向指標(metric)一些。
Would you be willing to disclose the percentage of scripts that's going through Blink now and kind of how that's trended so we can kind of track that given its importance? And then maybe just for investors to kind of better understand the benefits of going through Blink, can you just.
你們是否願意揭露目前有多少比例的處方是透過 Blink 進行,以及其趨勢如何,讓我們能因其重要性而追蹤?另外,為了讓投資人更了解透過 Blink 的好處,你們能否。
Kind of talk to us about PA approval rates, fill rates, and refill rates within Blink versus outside of Blink.
跟我們談談在 Blink 內與 Blink 之外的事前授權(PA)核准率、領藥率(fill rate)以及續配率(refill rate)的差異?
Again, so investors can clearly understand the benefit there.
同樣地,讓投資人能清楚理解其中的效益。
Steven Basta - President, Chief Executive Officer, Director
Steven Basta - President, Chief Executive Officer, Director
Chase, thanks so much for the questions.
Chase,非常感謝你的問題。
We're going to pass on providing a... Litany of metrics that we then would end up evaluating every quarter to look at how each one works. Just that level of granularity I don't think is going to be helpful, and I think it ends up creating lots of map and focus on each of the trends. But what you're describing is, in fact, what we are tracking internally. So what we are tracking internally is the percentage of scripts. In fact, there are many ways of looking at scripts. You can look at TRX dispensed and the TRX dispense rate coming out of Blink versus retail. We're looking at NRXs, we're looking at new-to-brand RXs, and we're looking at the pattern of prescribing that's going to blank. And we are seeing a shift associated with the introduction of our education initiatives that more of those new-to-brand scripts are landing at blank than had been before our access initiatives were implemented. So it is clearly moving the needle in the right direction.
我們會先不提供一長串指標,否則每一季都得逐一評估、檢視每個指標的表現。我認為那種細緻程度不一定有幫助,反而會造成大量的解讀與把焦點放在各個趨勢上。但你所描述的,確實是我們內部正在追蹤的內容。我們內部追蹤的是處方占比。事實上,處方也有很多種看法。你可以看已配藥的 TRx(總處方量)以及從 Blink 相較於零售端的 TRx 配藥率。我們也看 NRx(新處方)、看 new-to-brand Rx(首次使用本品牌的處方),並觀察處方流向 Blink 的開立模式。我們看到,隨著教育推廣措施的導入,更多 new-to-brand 處方比起我們實施可近性措施之前,更常落在 Blink。因此,這確實正在把指標往正確方向推進。
One thing for everybody to keep in mind though is as we move new-to-brand prescriptions to Blink, we will over time improve the PA submission rates. We will over time be improving the overall PA approval rates. We will be over time improving the overall dispense rate, but it has a very gradual impact because new-to-brand prescriptions turn into a meaningful TRX benefit as you get to multiple refills, which happen over the course of many.
不過大家要記住的一點是,當我們把更多 new-to-brand 處方導向 Blink,隨著時間推進,我們會提升 PA 送件率。我們也會逐步提升整體 PA 核准率。我們也會逐步提升整體配藥率(dispense rate),但其影響是很漸進的,因為 new-to-brand 處方要在多次續配後,才會轉化為有意義的 TRx 效益,而這會在許多。
So the incremental lift in new-to-brand scripts going to blink that might occur within Q4 has a greater impact because if a script goes in November or goes in December to blink, you get one fill in December, but you could get three fills in Q1 and multiple fills over the course of 2027. So that script has a greater impact on 2027. So you have an incremental build over time as the new-to-brand scripts turn into multiple TRXs. So the benefit of sending a script to Blink in terms of the metrics are a better conversion of new to brand scripts that more of those scripts get filled, better submission rates of prior authorizations, better approval rates for prior authorizations, and better refill rates that we're able to get over time because of the continuity of contact that Blink has on an ongoing basis with the office when the next prior authorization is required or the contact that they. Have with patients around the continuity of filling prescriptions. And if a patient drops off, they have the ability to contact the patient, see if they want to fill the script some months later. So there are a number of contact point advantages that occur through that channel that are better than the experience in a traditional retail pharmacy that over time will build toward more consistency of utilization and better depth of adoption.
因此,若在第四季內有增量的 new-to-brand 處方流向 Blink,影響會更大,因為如果一張處方在 11 月或 12 月進到 Blink,你可能在 12 月只拿到一次配藥,但在第一季可能拿到三次配藥,並在 2027 年期間獲得多次配藥。所以那張處方對 2027 年的影響更大。因此,隨著 new-to-brand 處方轉化為多次 TRx,效益會隨時間逐步累積。把處方送到 Blink 的好處(就指標而言)包括:new-to-brand 處方的轉換更好、更多處方能被實際配藥、事前授權的送件率更高、事前授權的核准率更高,以及因 Blink 能與診所持續保持聯繫(例如需要下一次事前授權時)或他們與病患之間在持續領藥方面的聯繫,而使我們能隨時間取得更好的續配率。並且在處方持續配藥的連續性上與病患保持互動。如果病患中斷用藥,他們也能聯絡病患,確認是否願意在幾個月後再領藥。因此,透過該通路會出現多個接觸點的優勢,這些都優於傳統零售藥局的體驗;長期而言,將帶來更一致的使用情況與更深度的採用。
But we'll provide the. On what the general parameters are that improve, I'll pass on providing the specific numbers.
但我們會提供。我們會說明哪些一般性參數會改善,但具體數字我們就先不提供。
Chase Knickerbocker - Analyst
Chase Knickerbocker - Analyst
Yeah, understood. And maybe just a little bit bigger picture kind of along those lines.
好的,了解。那也許再從更宏觀的角度、沿著這個方向問一下。
It seems like this kind of access conversation and improving that perception is probably your biggest lever to impact business momentum. Can you maybe just talk to kind of the other levers that you think you can pull from your seat that.
看起來這類可近性(access)的對話與改善外界觀感,可能是你們影響業務動能最大的槓桿。你們能否談談,從你們的角度還有哪些其他槓桿可以拉動。
Can further impact business momentum in addition to this access conversation.
除了這次關於可及性的對話之外,還可能進一步影響業務動能。
Steven Basta - President, Chief Executive Officer, Director
Steven Basta - President, Chief Executive Officer, Director
Well, so I think the access conversation is the first conversation that we need to have because we were finding that was the significant hurdle to broader adoption within GI offices.
嗯,所以我認為可及性對話是我們需要先進行的第一個對話,因為我們發現這是 GI 診所更廣泛採用的一個重大障礙。
What we found was. That gastroenterologists were using this product for their most severe patients because they were sort of weighing effectively how much does my patient need better acid suppression versus is this going to be a hassle for my staff or is my patient reliably going to get it? Am I going to have some difficulty in the process getting it to my patient? So as more and more, as we were having conversations with physicians over the past, six, 12 months, the.
我們發現的是。胃腸科醫師把這個產品用在他們最嚴重的病人身上,因為他們某種程度上是在權衡:我的病人到底需要更好的抑酸效果到什麼程度,對比這會不會讓我的員工很麻煩,或是我的病人能不能穩定拿到藥?我在把藥送到病人手上的流程中會不會遇到一些困難?所以在過去 6 到 12 個月裡,隨著我們與醫師進行越來越多的對話,這些對話的。
Volume of those conversations that was the trade-off that they were thinking about made it clear that what we need to do is solve this perception of access. It's actually not solving in reality when access we have. We've got really good market access coverage by payers, but the perception that it may be difficult or it may be expensive, we needed to get through that process. Once we've gotten through that process.
他們所思考的取捨的對話量,讓我們清楚知道我們需要做的是解決這種對可及性的認知。其實不是在現實中解決可及性,因為我們本來就有可及性。我們已經有保險支付方提供的非常好的市場准入覆蓋,但「可能很難取得」或「可能很昂貴」的這種認知,我們需要突破這個流程。一旦我們突破了這個流程。
We then open the door to conversations about broader populations of patients within their practice that could benefit from this product. So a patient who's been on PPI therapy and has significant nighttime heartburn becomes an appropriate patient for Voquezna because we can improve their heartburn symptoms by improving their acid suppression therapy. It broadens the utilization and it broadens the conversation about what patients are appropriate.
接著我們就能開啟與他們診所內更廣泛病人族群的對話,這些病人可能會從這個產品中受益。例如,一位一直在使用 PPI 治療且有明顯夜間胃灼熱的病人,就會成為 Voquezna 的合適病人,因為我們可以透過改善抑酸治療來改善其胃灼熱症狀。這會擴大使用範圍,也會擴大關於哪些病人適合使用的討論。
Right now we're focusing. On their erosive esophagitis patients where they have the greatest need, but we expect to broaden to multiple populations of patients over time. Step one is build confidence you can get it for your patient, get it reliably, and get it affordably. And then step two is going to be broaden their adoption in their severe patients. And then step three is broaden their adoption in multiple patient populations within their GERD patient base.
目前我們聚焦。在糜爛性食道炎病人身上,因為他們的需求最大,但我們預期隨著時間推進會擴展到多個病人族群。第一步是建立信心:你可以替病人拿到藥、能穩定拿到、而且能以可負擔的方式拿到。第二步將是擴大他們在重症病人中的採用。第三步則是在他們的 GERD 病人基礎中,擴大到多個病人族群的採用。
Chase Knickerbocker - Analyst
Chase Knickerbocker - Analyst
Makes sense. Thanks, Steve.
有道理。謝謝你,Steve。
Operator
Operator
Thank you. (Event Instructions) Our next question or comment comes from the line of Dennis Clark from Lyric. Mr. Clark, your line is now open.
謝謝。(活動指示) 我們下一個提問或評論來自 Lyric 的 Dennis Clark。Clark 先生,您的線路已開通。
Dennis Clark - Analyst
Dennis Clark - Analyst
Great. Thanks so much. Good morning. Steve, I wanted to ask, last quarter, you said that top Voquesna prescribers have the access process pretty dialed in. Would just be curious what percentage of prescribers you think are in a good place and what percentage. Could really benefit from the improved access programs that you're kind of laying out here this quarter. And then secondarily, just in terms of phasing, when you're thinking improved access tail might start to show up in revenue, just like an early part of 2027 story, second-half of 2027 story, any color there would be greatly appreciated.
很好。非常感謝。早安。Steve,我想問一下,上個季度你提到 Voquezna 的頂尖開立者已經把可及性流程掌握得很到位。我很好奇你認為有多少比例的開立者已經處於良好狀態,以及有多少比例。會真正受益於你們本季度在這裡提出的可及性改善方案。另外,關於分階段的時間點,當你在思考可及性改善的長尾效應何時會開始反映在營收上時,是像 2027 年初期的故事、還是 2027 年下半年的故事?若能提供一些看法將非常感謝。
Thank you.
謝謝。
Steven Basta - President, Chief Executive Officer, Director
Steven Basta - President, Chief Executive Officer, Director
Dennis, thanks so much for the question. And it's hard to put a specific percentage on prescribers that have this dialed in, for example, as a sort of characterization versus needing to improve. Almost every physician is on a continuum of building their confidence. Some are at the end of the continuum or further along the path of the continuum where they have much greater confidence in the product, but even in those physicians, there is more. Can be, even with those physicians, there's more that can be done. There is more education that we can do for them around the experience that their patients are having within Blink, the kind of reinforcement that we're able to offer, the support that we're able to offer to their staff, that even a physician who already has confidence in Vequesna, already is prescribing, and a fair portion of their scripts may be going to Blink already, and they think that they're using this solidly, they may still only be using it in their most severe. Your patients. And they may be one of our top prescribers, but if we're capturing 5%, 7% of their acid suppression prescriptions, we can get to 20% or 30% of their acid suppression prescriptions by increasing their awareness further and increasing their understanding of the support tools. And we are finding, for example, when we walk into offices showing them what the true patient out of pocket cost is, it surprises them. They think this drug is expensive because they heard from the one patient. That they recently prescribed and sent the script to CVS or Walgreens, and the patient called them up and said, Doc, oh my God, this drug is really expensive. I can't afford it, because that patient's insurance plan didn't cover the product, or the patient didn't know that we had a copay support program, so they got hit with a high copay program. And so the physician might have a perception that the drug is really expensive for most of their patients when we actually show them.
Dennis,非常感謝你的問題。而且很難對「哪些開立者已經把這件事掌握得很到位」給出一個具體百分比,作為一種描述,相對於仍需要改善。幾乎每位醫師都處在建立信心的連續光譜上。有些人已經在光譜的末端或更靠後的位置,對產品有更高的信心,但即便是這些醫師,也還有更多。即便是這些醫師,也還有更多事情可以做。我們仍可就病人在 Blink 的體驗、我們能提供的強化措施、以及我們能提供給其員工的支援,對他們做更多教育;即使一位醫師已經對 Vequesna 有信心、已經在開立,而且其處方中相當一部分可能已經走 Blink,他們也覺得自己用得很扎實,但他們可能仍只用在最嚴重的。病人身上。而且他們可能是我們的頂尖開立者之一,但如果我們只拿到他們抑酸處方的 5%、7%,透過進一步提升其認知並加深其對支援工具的理解,我們可以提升到他們抑酸處方的 20% 或 30%。例如,我們發現當我們走進診所,向他們展示病人實際自付費用是多少時,常常會讓他們感到驚訝。他們以為這個藥很貴,因為他們聽到某一位病人。他們最近開了處方並把處方送到 CVS 或 Walgreens,病人打電話給他們說:醫師,天啊,這個藥真的很貴。我負擔不起,因為那位病人的保險方案沒有涵蓋該產品,或病人不知道我們有共付額(copay)支援計畫,所以被收了很高的共付額。因此,醫師可能會認為對他們大多數病人來說這個藥都很貴,但當我們實際向他們展示。
What the average cost is for patients that are getting the drug and what the true affordability programs are. This is also one of the advantages. I know I've mentioned a couple of times on this call, but this is one of the advantages of the $0 copay program is that it sparks that conversation so that even our significant volume prescribers still may have elements. Of their perception that are holding them back from prescribing from our broader population of patients because they don't want to prescribe a drug that they think their patient can't afford. When they realize that it's $0 out of pocket for many of their patients, that changes the conversation. And we can deepen the adoption even among our top prescribers, and we can deepen the adoption all the way through the prescribing base. So we view every prescriber as being on a continuum from just starting. Prescribing and just learning about how our access programs work and our support programs to having deep knowledge and confidence in those programs. And what we're trying to do is move them along that continuum to a greater level of confidence, a greater level of awareness, and the aha realization, I really can get this drug from my patients. It's just not that hard. It's easy to do, and they're going to get it affordably. When they get to that level of confidence, that's when we're going to start deepening their prescribing. And even there, once they get to that level of confidence, we then have to have the education about who are all the. Patients in your practice that could benefit from better acid suppression.
病人取得該藥的平均成本是多少,以及真正的可負擔性方案是什麼。這也是其中一個優勢。我知道我在這通電話裡提過幾次,但這是 0 美元共付額計畫的優勢之一:它會引發這個對話,因此即使是我們處方量很大的開立者,仍可能有一些。認知上的因素在阻礙他們把處方擴展到更廣泛的病人族群,因為他們不想開一個他們認為病人負擔不起的藥。當他們意識到對許多病人而言自付額是 0 美元時,對話就改變了。我們可以加深即便在頂尖開立者中的採用,也可以在整個開立者基礎中加深採用。因此我們把每位開立者都視為處在一個連續光譜上:從剛開始。開立、剛開始了解我們的可及性方案與支援方案如何運作,到對這些方案有深度知識與信心。而我們要做的是推動他們沿著這個光譜前進,達到更高的信心、更高的認知,以及「啊哈」的體會:我真的可以替我的病人拿到這個藥。其實沒有那麼難。做起來很容易,而且他們能以可負擔的方式拿到。當他們達到那個信心水準時,我們就會開始加深他們的開立。而即便到了那一步,一旦他們有了那個信心水準,我們接著還必須教育:在你的。診所裡有哪些病人能從更好的抑酸治療中受益。
Dennis, thanks so much for the question.
Dennis,非常感謝你的問題。
Dennis Clark - Analyst
Dennis Clark - Analyst
Thank you.
謝謝。
Operator
Operator
Ladies and gentlemen, this concludes the Q&A question.
各位女士、先生,問答環節到此結束。
Thank you for your presentation. This concludes the program. You may now disconnect. Everyone, have a wonderful day. Speak and standby.
感謝各位的簡報。本次活動到此結束。您現在可以斷線。祝各位有美好的一天。發言並待命。